PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ChemImage Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

James S. McGlone Joins ChemImage Corporation as President - ChemImage, a leader in Chemical Imaging technology, is pleased to announce the addition of James S. McGlone to the executive management team. James S. McGlone joined ChemImage effective June 1st, 2008
James S. McGlone Joins ChemImage Corporation as President

 

NewswireToday - /newswire/ - Pittsburgh, PA, United States, 2008/06/17 - ChemImage, a leader in Chemical Imaging technology, is pleased to announce the addition of James S. McGlone to the executive management team. James S. McGlone joined ChemImage effective June 1st, 2008.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“I am very excited about the opportunity at ChemImage.”James S. McGlone stated. “I look forward to exploiting ChemImage’s strong patent portfolio and leveraging our unique Molecular and Chemical Imaging abilities. With our unique abilities we will differentiate ourselves from other suppliers of imaging technologies.”

McGlone is the most recent addition to the ChemImage management team that has been transitioning over the last seven months. “We are extremely pleased that Mr. McGlone has joined the ChemImage family,” stated John Belechak, ChemImage Chief Operating Officer. “Jim’s an experienced business professional with firmly established leadership skills. He affords ChemImage the ability to think strategically at a higher level and provides invaluable business expertise,” Belechak added.

McGlone joins ChemImage after several years as the President of Galil Medical where he drove the expansion of Galil’s cryotherapy business. McGlone was also the President of Oncura which was a joint venture between General Electric (NYSE:GE) and Galil Medical, Ltd. Prior to joining Galil Medical, McGlone spent fourteen years in various sales and management roles with Siemens Medical Systems Inc., a subsidiary of Siemens AG (NYSE:SI).

McGlone holds an MBA from Stern Business School at New York University, a MS in Bioengineering from the Pennsylvania State University and a BA in Engineering and Applied Science from Yale University.

About ChemImage
ChemImage Corporation (chemimage.com) is a world leader in Chemical Imaging technologies; provides instrumentation, software and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.

ChemImage’s main headquarters is located in Pittsburgh, Pennsylvania and houses research and development laboratories as well as engineering and manufacturing facilities.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ChemImage Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


James S. McGlone Joins ChemImage Corporation as President

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Linda Batykefer - ChemImage.com 
412-241-7335 x269 batykefer[.]chemimage.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChemImage Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ChemImage Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)